Company
Queen City Angels leads the SalivIQ Seed round
Queen City Angels is the lead investor in the SalivIQ Seed round, backing the move from validated protocol to a clinic-ready product.
A lead investor for the Seed round
We are thrilled to announce that Queen City Angels is the lead investor in the SalivIQ Seed round. The round follows a successfully closed Pre-Seed and moves us from a validated laboratory protocol toward a product that can sit in a clinic.
Where the funding goes
The capital supports three things: continued work through the FDA pathway, the manufacturing partnership that will produce the test at scale, and the clinical evaluation work needed to put SalivIQ Strep A in front of the clinicians who will use it.
We are grateful to our investors for backing a diagnostic that patients actually prefer and clinicians can act on in a single visit.
keep reading
